Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Cited by
Choi, I. Y., Piccio, L., Childress, P., Bollman, B., Ghosh, A., Brandhorst, S., Suarez, J., Michalsen, A., Cross, A. H., Morgan, T. E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.009 · Cited by 505
White matter and cognition: making the connection
Filley, C. M., & Fields, R. D. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00221.2016 · Cited by 443
Atkins, H. L., Bowman, M., Allan, D., Anstee, G., Arnold, D. L., Bar-Or, A., Bence-Bruckler, I., Birch, P., Bredeson, C., Chen, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30169-6 · Cited by 325
Effector T Cells in Multiple Sclerosis
Kaskow, B. J., & Baecher-Allan, C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029025 · Cited by 314
Tourbah, A., Lebrun-Frenay, C., Edan, G., Clanet, M., Papeix, C., Vukusic, S., De Sèze, J., Debouverie, M., Gout, O., Clavelou, P., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516667568 · Cited by 302
Cadavid, D., Balcer, L., Galetta, S., Aktas, O., Ziemssen, T., Vanopdenbosch, L., Frederiksen, J., Skeen, M., Jaffe, G. J., Butzkueven, H., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30377-5 · Cited by 273
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 256
Control of autoimmune CNS inflammation by astrocytes
Rothhammer, V., & Quintana, F. J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0515-3 · Cited by 214
Choi, I. Y., Lee, C., & Longo, V. D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.042 · Cited by 133
Disanto, G., Benkert, P., Lorscheider, J., Mueller, S., Vehoff, J., Zecca, C., Ramseier, S., Achtnichts, L., Findling, O., Nedeltchev, K., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152347 · Cited by 76
Environmental control of autoimmune inflammation in the central nervous system
Rothhammer, V., & Quintana, F. J. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.09.002 · Cited by 52
“In 15%, MS takes a progressive course from its beginning (primary progressive MS, PPMS) [3,4].”
BackgroundRecent Trends in Nanotechnology Toward CNS Diseases
Cardoso, A. M., Guedes, J. R., Cardoso, A. L., Morais, C., Cunha, P., Viegas, A. T., Costa, R., Jurado, A., & Pedroso de Lima, M. C. (2016) · International Review of Neurobiology · doi:10.1016/bs.irn.2016.05.002 · Cited by 26
Metadata
- Authors
- Wingerchuk, D. M., & Carter, J. L.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 89
- Issue
- 2
- Pages
- 225-240
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W2042166711
- Cited by
- 416
- References
- 116
- FWCI
- 36.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.